menu
    • menu
    [{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"James Madison University","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ James Madison University","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ James Madison University"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"NM Clinical Research & Osteoporosis Center","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ NM Clinical Research & Osteoporosis Center","highestDevelopmentStatusID":"6","companyTruncated":"Canopy Growth Corporation \/ NM Clinical Research & Osteoporosis Center"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Canopy Growth Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Canopy Growth Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Canopy Growth Corporation \/ Canopy Growth Corporation"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Canopy Growth Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Cannabis","moa":"Cannabinoid receptor 1; Cannabinoid receptor 2; G-protein coupled receptor 12; Glycine receptor subunit alpha-1; Glycine receptor (alpha-1\/beta); Glycine receptor subunit alpha-3; N-arachidonyl glycine receptor; G-protein coupled receptor 55; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A; Neuronal acetylcholine receptor subunit alpha-7; Delta-type opioid receptor; Mu-type opioid receptor; Peroxisome proliferator-activated receptor gamma; Transient receptor potential cation channel subfamily V member 1; Voltage-dependent T-type calcium channel subunit alpha-1G; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-dependent T-type calcium channel subunit alpha-1I; Transient receptor potential cation channel subfamily A member 1; Transient receptor potential cation channel subfamily M member 8; Transient receptor potential cation channel subfamily V member 2; Transient receptor potential cation channel subfamily V member 3; Transient receptor potential cat","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Canopy Growth Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Canopy Growth Corporation \/ Canopy Growth Corporation"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"cannabinol derivatives","graph1":"Undisclosed","graph2":"Phase I","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Canopy Growth Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CHI-202","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"University of Arkansas","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CHI-554","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oil","sponsorNew":"Canopy Growth Corporation \/ University of Arkansas","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ University of Arkansas"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CHI-560","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Canopy Growth Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Centre for Addiction and Mental Health | McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CHI-902","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Canopy Growth Corporation \/ Centre for Addiction and Mental Health | McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ Centre for Addiction and Mental Health | McMaster University"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Galenova Inc | Algorithme Pharma Inc. | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CHI-921","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Canopy Growth Corporation \/ Galenova Inc | Algorithme Pharma Inc. | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ Galenova Inc | Algorithme Pharma Inc. | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal"}]

    Find Clinical Drug Pipeline Developments & Deals by Canopy Growth Corporation

    Menu

    Canopy Growth Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CHI-560

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on ...

                            Details : CHI-560 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 03, 2023

                            Lead Product(s) : CHI-560

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : James Madison University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effects of CBD Isolate on Menstrual-Related Symptoms

                            Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Menstruation Disturbances.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            January 11, 2023

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : James Madison University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Johns Hopkins University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Pharmacodynamics of Cannabinoid-Caffeine Combinations

                            Details : Tetrahydrocannabinol is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            July 28, 2022

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Johns Hopkins University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabis

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Recipient : Johns Hopkins University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants

                            Details : Cannabis is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Marijuana Abuse.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            April 13, 2022

                            Lead Product(s) : Cannabis

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Recipient : Johns Hopkins University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : NM Clinical Research & Osteoporosis Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CBD in Postmenopausal Women With Osteopenia

                            Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bone Diseases, Metabolic.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 07, 2022

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : NM Clinical Research & Osteoporosis Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabivarin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants

                            Details : THCv is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 27, 2022

                            Lead Product(s) : Tetrahydrocannabivarin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CHI-202

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

                            Details : CHI-202 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myalgia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 30, 2021

                            Lead Product(s) : CHI-202

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CHI-554

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : University of Arkansas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Randomized Controlled Test of the Effects of CHI-554 on Fear.

                            Details : CHI-554 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anxiety.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 08, 2020

                            Lead Product(s) : CHI-554

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : University of Arkansas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CHI-902

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Centre for Addiction and Mental Health | McMaster University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CHI-902 for Treatment of Social Anxiety Disorder

                            Details : CHI-902 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Phobia, Social.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 11, 2019

                            Lead Product(s) : CHI-902

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Centre for Addiction and Mental Health | McMaster University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Canopy Growth Corporation

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CHI-921

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Galenova Inc | Algorithme Pharma Inc. | Hôpital du Sacre-Cœur de Montréal | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigation of the Efficacy and Safety of CHI-921 in Insomnia.

                            Details : CHI-921 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 13, 2019

                            Lead Product(s) : CHI-921

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Galenova Inc | Algorithme Pharma Inc. | Hôpital du Sacre-Cœur de Montréal | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth